Treace Medical Preliminary Q4, FY24 Revenues Beat Expectations; Stock Up

(RTTNews) - Treace Medical Concepts, Inc. (TMCI), Monday announced preliminary revenue for the fourth quarter and full year 2024, revealing an increase of nearly 10 percent and 12 percent, respectively, at the midpoint over the same period last year.

The medical technology company estimates preliminary revenue of $68.4 million to $68.8 million for the fourth quarter, and $209 million to $209.4 million for the fiscal year 2024.

Analysts, on average, predict revenue of $67.02 million for the fourth quarter, and $207.58 million for the full year 2024.

Currently, Treace's stock is climbing 12.64 percent, to $8.20 on the Nasdaq.